Mother-Infant Dyad & Integrated SUD Care
Deep Dive Materials

About This Enrichment Document: This companion to the clinical guide provides extended references, detailed case analyses, implementation tools, policy considerations, and emerging research updates for clinicians seeking deeper expertise in perinatal SUD care.

Extended References & Evidence Base

Primary Studies

1. Integrated Care Outcomes (St. Michael's Hospital, 2023)
Retrospective cohort of 127 pregnant individuals with OUD. Co-located OB-Addiction care reduced preterm birth from 26.6% to 11.8% (p<0.01) and increased treatment retention to 94% vs 67% in fragmented care (p<0.001).

2. ESC-NOW Trial (NIH/NICHD, 2023)
Multicenter RCT (n=1,305) demonstrated 6.7-day reduction in length of stay and 63% reduction in pharmacotherapy with Eat, Sleep, Console vs Finnegan-based care. Cost savings: $12,400 per infant.

3. Missouri PQC SUD Bundle (2019-2024)
Statewide quality collaborative implementing AIM bundle across 67 birthing hospitals. Screening rates increased 47.9% (to 99%), maternal safe plans increased 144.4% (to 90.5%).

Guidelines & Frameworks

Detailed Case Studies for Teaching

Case 1: Complex Trauma and OUD

Patient: 24-year-old G1P0 at 18 weeks, history of childhood sexual abuse, current intimate partner violence, daily heroin use. Presents to ED with withdrawal.

Clinical Decisions:

  • Initiated buprenorphine 8mg BID using "low and slow" approach given trauma sensitivity
  • Immediate IPV safety planning and shelter referral
  • PTSD-informed care: avoided retraumatization, allowed support person during exams
  • Plan of Safe Care developed with CPS liaison before any CPS notification

Outcome: Continued buprenorphine through delivery. Infant with mild NOWS managed non-pharmacologically. Patient engaged in trauma therapy, obtained restraining order, transitioned to safe housing.

Teaching Points: Trauma-informed care is not optional—it's essential for engagement. IPV and SUD often co-occur; address safety first. CPS collaboration can be supportive, not adversarial.

Case 2: Late Presentation and Rapid Engagement

Patient: 32-year-old G3P2 at 36 weeks, no prenatal care, arrives in active labor with opioid withdrawal.

Clinical Decisions:

  • Immediate methadone initiation per hospital protocol (20mg initial dose)
  • Anesthesia consult for multimodal pain management
  • Pediatric team alerted for NOWS monitoring using ESC approach
  • 48-hour stay with intensive social work intervention

Outcome: Delivered at 37 weeks. Infant with moderate NOWS, managed with oral morphine wean over 7 days. Mother linked to outpatient OTP with weekly follow-up.

Teaching Points: Late engagement is common—don't judge. Emergency MOUD initiation is safe and effective. The 48-72 hour post-birth window is critical for establishing outpatient linkage.

Implementation Tools

1. Plan of Safe Care Template

DomainAssessment QuestionsAction Items
Maternal HealthMOUD provider? OB follow-up scheduled? Mental health needs?List providers, dates, contact info
Infant HealthPediatrician identified? NOWS risk level? Early intervention referral?Pediatric appointment, feeding plan
SafetySafe sleep plan? Housing stability? IPV screening?Sleep education, shelter if needed
Social SupportFamily support? Recovery community? WIC enrollment?Peer specialist, support group

2. Warm Handoff Checklist

3. Non-Stigmatizing Language Guide

Instead of...Use...
Addict, abuser, junkiePerson with OUD, person in recovery
Clean/dirty urineUrine toxicology consistent with prescribed medications; substance detected
The addict in Room 3Patient with OUD in Room 3
Non-compliantChallenges with adherence, barriers to care
Failed treatmentRelapse, return to use

Policy Considerations

CAPTA/CARA Requirements

Key Legal Distinction: CAPTA requires states to have policies and procedures for notifying child protective services of substance-exposed infants. However, this notification is NOT a finding of abuse or neglect—it is a mechanism to connect families to services. States have discretion in how they implement this requirement.

State-by-State Variation

Advocacy Opportunities

Emerging Research Updates

Tele-MOUD in Pregnancy

Recent studies (2023-2024) demonstrate equivalent outcomes for telehealth-initiated buprenorphine vs in-person care in pregnancy. Key considerations:

Extended-Release Buprenorphine

Monthly injectable buprenorphine (Sublocade) is increasingly used in pregnancy. Limited but growing evidence suggests safety and efficacy. Consider for patients with:

NOWS Prediction Models

Machine learning algorithms using maternal factors (MOUD type/dose, polysubstance use) show promise for predicting NOWS severity. Not yet validated for clinical decision-making but may guide resource allocation.

Additional Resources